Showing results (171-180 of 412) with videos related to

Sort By:
Pageof 42
Haematologica|October 21, 2016
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndromeMonique C Minnema, Eva Kimby, Shirley D'Sa, et al.
American Journal of Hematology|March 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström MacroglobulinemiaJorge J Castillo, Andrew R Branagan, Alberto Guijosa, et al.
Blood|April 13, 2012
Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studiesJorge J Castillo, Nikhil Mull, John L Reagan, et al.
American Journal of Hematology|December 19, 2019
Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphomaAdam J Olszewski, James N Butera, John L Reagan, et al.
British Journal of Haematology|January 24, 2015
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphomaJorge J Castillo, John L Reagan, William M Sikov, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2014
Hematopoietic cell transplantation for plasmablastic lymphoma: a reviewMonzr M Al-Malki, Jorge J Castillo, J Mark Sloan, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemiaLeukothea Ioakimidis, Christopher J Patterson, Zachary R Hunter, et al.
Leukemia & Lymphoma|December 10, 2021
Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in ChileMaría Elena Cabrera, Neda Marinov, Macarena Roa, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2012
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemiaSteven P Treon, Christina Tripsas, Christina Hanzis, et al.
British Journal of Haematology|May 20, 2003
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cellsToshiaki Hayashi, Steven P Treon, Teru Hideshima, et al.
Pageof 42